Strengths

● Analysts covering this company mostly recommend stock overweighting or purchase.


Weaknesses

● Stock prices approach a strong long-term resistance in weekly data at EUR 13.3.

● The stock is close to a major daily resistance at EUR 13.5, which should be gotten rid of so as to gain new appreciation potential.

● The company is in debt and has limited leeway for investment

● Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 46.21 times its estimated earnings per share for the ongoing year.

● The company is not the most generous with respect to shareholders' compensation.

● For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.

● For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

● For the past year, analysts have significantly revised downwards their profit estimates.